Lumos Diagnostics Holdings Ltd. · ASX:LDX
Lumos Diagnostics — Q4 FY25 Earnings Presentation
30 slides from Lumos Diagnostics's earnings presentation, Jul 21, 2025
Slide 1: Lumos Diagnostics Holdings Limited Investor Briefing
For personal use only Lumos Diagnostics Holdings Limited Investor Briefing 21 July 2025 Financial information is shown in USD unless otherwise stated. www.lumosdiagnostics.com © Lumos Diagnostics . All rights reserved. 1
Slide 2: Disclaimer and Important Information
Disclaimer and Important Information This presentation (Presentation) has been prepared solely for informational purposes by Lumos Diagnostics Holdings Limited representation, as to the past, present or the future. Past performance is not necessarily a guide to future likelihood of For personal use
Slide 3: Lumos develops, manufactures and distributes innovative diagnostic products
For personal use only Lumos develops, manufactures and distributes innovative diagnostic products – delivering actionable information, in real time, at the point-of-care. © Lumos Diagnostics , all rights reserved 3
Slide 4: Company Overview
Company Overview Experienced leadership team For personal use only Comprehensive & integrated offering from product concept design through to manufacture and distribution Developed and launched one of kind proprietary point-of-care diagnostic products - FebriDx Transformational development agreement
Slide 5: Lumos Business Overview
Lumos Business Overview For personal use only Lumos offers end-to-end point of care (POC) diagnostic test PRODUCTS COMMERCIAL SERVICES development, from initial assay creation to high-volume manufacturing. We develop FebriDx Women’s Development Contract and sell our own tests and also Health manufac
Slide 6: Investment Highlights
Investment Highlights Proprietary product FebriDx® (bacterial v non-bacterial test) generating sales in market For personal use only Pivotal distribution contract Major agreement signed with PHASE Scientific for the U.S. market – for US$317 million (A$487 million1) over 6 years,2 assuming FebriDx® g
Slide 7: Key Q4 FY25 Highlights
For personal use only Key Q4 FY25 Highlights
Slide 8: Key highlights from Q4 FY25 & post reporting date
Key highlights from Q4 FY25 & post reporting date For personal use only $ Revenue of $12.4 million for the year, up 12% Major distribution agreement signed with Lumos U.S. Medicare payor coverage for compared to prior year (FY24 - $11.1 million). PHASE Scientific for the U.S. market - for FebriDx®,
Slide 9: Financials summary
Financials summary (Quarterly, US$ in thousands) Revenue ($’000) Revenue Mix Net Cash Generation ($’000)* For personal use only 100% $4,340 $3,117 $3,421 80% $3,470 $2,885 $2,625 60% 40% 20% -$1,583 -$1,979 -$2,791 0% -$3,980 Q4FY24 Q1FY25 Q2FY25 Q3FY25 Q4FY25 Q4FY24 Q1FY25 Q2FY25 Q3FY25 Q4FY25 Q4FY
Slide 10: Binding term sheet for loan facility – July 2025
Binding term sheet for loan facility – 17 July 2025 For personal use only Binding term sheet signed with supportive major shareholders Tenmile and Ryder Capital Funding of up to A$5.0 million, as required, on 12-month term, with option to extend by a further 12-months The loan is designed to provide
Slide 11: Products Division
For personal use only Products Division
Slide 12: PHASE Scientific partnership
PHASE Scientific partnership A pivotal agreement - one of the largest distribution deals of its type to be done by an ASX-listed point of care diagnostics company For personal use only Exclusive U.S. distribution agreement signed for FebriDx® with PHASE Scientific International Partnership potential
Slide 13: PHASE Scientific exclusive FebriDx U.S. distribution agreement
PHASE Scientific exclusive FebriDx® U.S. distribution agreement Summary of anticipated payments (US$) For personal use only Milestones Payment Timing With CLIA waiver Summary of key terms • Six-year term, with option to extend Exclusivity fee On signing 1.0m • Exclusive rights to distribute and comm
Slide 14: About FebriDx: Lumos' first-of-its-kind point of care test
About FebriDx®: Lumos’ first-of-its-kind point of care test FebriDx® is an aid for healthcare providers to improve patient care and antibiotic stewardship For personal use only The majority of acute respiratory infections are caused by viruses and do not require antibiotics, yet antibiotics are pres
Slide 15: FebriDx addresses a major need: antibiotic overprescription
FebriDx® addresses a major need: antibiotic overprescription ANTIBIOTICS PRESCRIBED (U.S.) ANTIBIOTICS PRESCRIBED IN THE U.S. BY TYPE For personal use only Common cold Sinusitis Other infections Bronchitis Sore throat Ear infection 211M antibiotic prescriptions issued in outpatient settings each yea
Slide 16: FebriDx journey to transform the practice of medicine
FebriDx® journey to transform the practice of medicine Recent achievements forming the critical commercialisation backbone for FebriDx® For personal use only July 2025 Funding agreement announced with major July 2025 shareholders to Lumos announces support Lumos major partnership with through to CLI
Slide 17: FebriDx CLIA waiver study update
FebriDx® CLIA waiver study update BARDA partnership agreement announced in October 2024 For personal use only • BARDA partnership agreement: non-dilutive funding up to US$8.3 million committed to support CLIA waiver and pediatric studies (US$3.0m for CLIA waiver study and US$5.3m for pediatric study
Slide 18: FebriDx market opportunity in the U.S. > $1 Billion
FebriDx® market opportunity in the U.S. > $1 Billion A CLIA waiver grant enables facilities (e.g., physician offices, stand alone urgent care centers) to perform diagnostics without laboratory oversight For personal use only MODERATE COMPLEXITY LIMITATION CLIA WAIVER EXPANDS ADDRESSABLE MARKET Poten
Slide 19: Why partner with PHASE Scientific?
Why partner with PHASE Scientific? For personal use only Expertise and understanding of the POC market in the U.S. Highly regarded, well respected commercial leadership Financial commitment to a robust go-to-market launch for FebriDx® Strong network of sub- distributors and end user customers. © Lum
Slide 20: Introducing PHASE Scientific
Introducing PHASE Scientific • Operations in the U.S., mainland China, and Hong Kong For personal use only • Delivering novel diagnostic tools and services for cancer and infectious diseases using proprietary technologies • Products/services: received certifications from the U.S. Food and Drug Admin
Slide 21: Lumos Future Products
Lumos Future Products Women’s Sexual Health - $10B For personal use only 1-2 DAYS Prevalence Clinical Need POC Diagnostic Opportunity Affects 30%-40% of women globally. Multiple infectious organisms. Rapid & accurate testing close to the >10M heath care visits annually in the Similar symptoms / hard
Slide 22: Women's Sexual Health – The Opportunity
Women’s Sexual Health – The Opportunity IN CLINIC TESTING EXTERNAL LAB TESTING For personal use only Physical Exam Microscopic Exam Pathogen Testing Pathogen Testing 1-5 DAYS Practice Current Majority of clinics do not have in Instead, clinics send out testing to Lumos Women’s Sexual Health POC test
Slide 23: Lumos Product Roadmap | Women's Sexual Health
Lumos Product Roadmap | Women’s Sexual Health CURRENT - DISTRIBUTION FUTURE - LUMOS POC PRODUCTS GYN CLINIConly Revenue & Market Learning Pathogen Detection | Visual & Reader Interpretation URGENT CARE For personal use & Lumos – As a Distributer Lumos Products – Visual Read Lumos Products on Lumos R
Slide 24: Commercial Services Division
For personal use only Commercial Services Division © Lumos Diagnostics . All rights reserved. 24
Slide 25: Commercial Services Capabilities
Commercial Services Capabilities For personal use only Lumos offers the full range of in-house expertise required to deliver a complete, commercially ready solution. DEVELOPMENT & MANUFACTURING PLATFORM TECHNOLOGIES ASSAY READERS EMR & CONNECTIVITIY © Lumos Diagnostics . All rights reserved. 25
Slide 26: How we add value to partners
How we add value to partners We work with partners through the whole diagnostic product development cycle, then provide support once their products are in market. For personal use only Customer launch and support Manufacture Clinical studies Verification and validation of requirements Conduct feasib
Slide 27: Hologic - strategic partnership
Hologic - strategic partnership Fetal Fibronectin (fFN)1 For personal use only Historic relationship with Lumos <> Hologic – fFN is a biomarker indicating a heightened risk working together at multiple levels of pre-term delivery and is the largest segment of the pre-term birth diagnostic kit market
Slide 28: Hologic - fFN Product development overview and opportunity
Hologic - fFN Product development overview and opportunity For personal use only Current test: Next generation test Hologic – the opportunity ahead Rapid fFN TLiQ concept (mock-up) Verification Clinical and validation study Manufacturing Second test development and IP © Lumos Diagnostics . All right
Slide 29: Key Priorities
Key Priorities For personal use only Complete CLIA waiver Implement agreement with Initiate FebriDx pediatric Deliver on Hologic fFN Progress to formal product study for FebriDx and PHASE Scientific, drive study in coming month’s – development milestones - development on the first submit application
Slide 30: Lumos Diagnostics Holdings Limited Investor Briefing
For personal use only Lumos Diagnostics Holdings Limited Investor Briefing www.lumosdiagnostics.com © Lumos Diagnostics . All rights reserved. 30
Lumos Diagnostics Holdings — Q4 FY25 Earnings Presentation on 6ix